American Journal of Hypertension

Journal

Publication Venue For

  • Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group.  32:1146-1153. 2019
  • Ethnic Differences in Nighttime Melatonin and Nighttime Blood Pressure: A Study in European Americans and African Americans.  32:968-974. 2019
  • Cardioprotective Effects of Paricalcitol Alone and in Combination with FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies.  32:34-44. 2019
  • Health Behaviors, Nocturnal Hypertension, and Non-dipping Blood Pressure: The coronary artery risk development in young adults and jackson Heart study.  32:759-768. 2019
  • Serum Sodium and Pulse Pressure in SPRINT.  32:649-656. 2019
  • Long-term effects of an intensive lifestyle intervention on electrocardiographic criteria for left ventricular hypertrophy: The look AHEAD trial.  31:541-548. 2018
  • Antihypertensive Medications and Falls in the Elderly.  31:281-283. 2018
  • The New ACC/AHA Hypertension Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.  31:133-135. 2018
  • West African ancestry and nocturnal blood pressure in African Americans: The Jackson Heart Study.  31:706-714. 2018
  • Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated with Elevated Urinary Mitochondrial-DNA Copy Number.  30:1112-1119. 2017
  • Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension.  30:103-109. 2017
  • 11-beta dehydrogenase type 2 activity is not reduced in treatment resistant hypertension.  30:518-523. 2017
  • Cumulative exposure to systolic blood pressure during young adulthood through midlife and the urine albumin-to-creatinine ratio at midlife.  30:502-509. 2017
  • Effects of spironolactone and renal denervation treatment on blood pressure and its variability-different aspects of hypertension treatment.  30:12-15. 2017
  • Update From the Editors to Our Readers..  30:1-2. 2017
  • Do we need a new definition of hypertension after SPRINT.  29:1127-1129. 2016
  • Psychosocial Correlates of Nocturnal Blood Pressure Dipping in African Americans: The Jackson Heart Study.  29:904-912. 2016
  • Potential Errors and Omissions Related to the Analysis and Conclusions Reported in Cuspidi C, et al., AJH 2014; 27(2):146-156.  29:780-781. 2016
  • A message from the new editorial team at the American Journal of Hypertension.  29:1. 2016
  • Clock genes explain a large proportion of phenotypic variance in systolic blood pressure and this control is not modified by environmental temperature.  29:132-140. 2016
  • Is isolated nocturnal hypertension a reproducible phenotype?.  29:33-38. 2016
  • SPRINT proves that lower is better for nondiabetic high-risk patients, but at a price.  29:2-4. 2016
  • Systolic blood pressure control among individuals with type 2 diabetes: A comparative effectiveness analysis of three interventions.  28:995-1009. 2015
  • Is pulse pressure an independent risk factor for incident stroke, REasons for geographic and racial differences in stroke.  28:987-994. 2015
  • Nocturnal blood pressure in young adults and cognitive function in midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) study.  28:1240-1247. 2015
  • Predictors of silent myocardial ischemia in resistant hypertensive patients.  28:200-207. 2015
  • Racial differences in abnormal ambulatory blood pressure monitoring measures: Results from the coronary artery risk development in young adults (CARDIA) study.  28:640-648. 2015
  • Prehypertension and incident acute coronary heart disease in the reasons for geographic and racial differences in stroke (Regards) study.  27:245-251. 2014
  • Achieved blood pressures in the secondary prevention of small subcortical strokes (SPS3) study: Challenges and lessons learned.  27:1052-1060. 2014
  • Hemodynamic and echocardiographic profiles in african american compared with white offspring of hypertensive parents: The HyperGEN study.  27:21-26. 2014
  • Is pulse pressure an independent risk factor for incident acute coronary heart disease events? the REGARDS study.  27:555-563. 2014
  • Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats.  27:720-726. 2014
  • Blood pressure after recent stroke: Baseline findings from the secondary prevention of small subcortical strok.  26:1114-1122. 2013
  • Blood pressure indexes and end-stage renal disease risk in adults with chronic kidney disease.  25:789-796. 2012
  • Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension.  24:708-715. 2011
  • Moderate waist circumference and hypertension prevalence: The REGARDS study.  24:482-488. 2011
  • Prehypertension, racial prevalence and its association with risk factors: Analysis of the reasons for geographic and racial differences in stroke (REGARDS) study.  24:194-199. 2011
  • Adjusting adiposity and body weight measurements for height alters the relationship with blood pressure in children.  23:904-910. 2010
  • The association of cell cycle checkpoint 2 variants and kidney function: Findings of the family blood pressure program and the atherosclerosis risk in communities study.  22:552-558. 2009
  • Prenatal programming: Maybe not so hopeless after all?.  22:348. 2009
  • Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.  18:805-812. 2005
  • A summary of the effects of antihypertensive medications on measured blood pressure.  18:935-942. 2005
  • A unifying pathway for essential hypertension.  18:431-440. 2005
  • Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals.  18:287-294. 2005
  • Genome-wide linkage analyses for age at diagnosis of hypertension and early-onset hypertension in the HyperGEN study.  17:839-844. 2004
  • Determinants of radial artery pulse wave analysis in asymptomatic individuals.  17:647-653. 2004
  • Advanced glycation end-product cross-link breakers: A novel approach to cardiovascular pathologies related to the aging process.  17:S23-S30. 2004
  • Genome scan for hypertension in nonobese African Americans: The National Heart, Lung, and Blood Institute Family Blood Pressure Program.  17:834-838. 2004
  • Efficacy of low-dose spironolactone in subjects with resistant hypertension..  16:925-930. 2003
  • Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events.  16:265-269. 2003
  • A Genome-Wide Linkage Analysis Investigating the Determinants of Blood Pressure in Whites and African Americans.  16:151-153. 2003
  • Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension.  16:51-58. 2003
  • Efficacy of Low-Dose Spironolactone in Subjects with Resistant Hypertension.  16:925-930. 2003
  • Are there meaningful differences in blood pressure control with current antihypertensive agents?.  15:14S-21S. 2002
  • Obesity: Its time has come.  15:655-656. 2002
  • Arterial compliance abnormalities in isolated systolic hypertension.  14:1007-1011. 2001
  • Urinary excretion of vasoactive factors are correlated to sodium excretion.  14:1003-1006. 2001
  • Elevated potassium intake inhibits neointimal proliferation in the swine coronary artery.  14:879-886. 2001
  • Cardiovascular effects of estrogen..  14:186S-193S. 2001
  • The role of the central nervous system in NaCl-sensitive hypertension in spontaneously hypertensive rats..  14:155S-162S. 2001
  • Blood pressure and arterial compliance in young adults: The Minnesota Children's Blood Pressure Study.  14:200-205. 2001
  • Factors affecting blood pressure responses to diet: The vanguard study.  13:956-965. 2000
  • High potassium intake inhibits neointima formation in the rat carotid artery balloon injury model.  13:1014-1020. 2000
  • Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The life study.  13:899-906. 2000
  • Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint..  13:899-906. 2000
  • Insulin and hypertension in the NHLBI family heart study.  13:240-250. 2000
  • Newly emerging pharmacologic differences in angiotensin II receptor blockers.  13. 2000
  • Newly emerging pharmacologic differences in angiotensin II receptor blockers..  13:18S-24S. 2000
  • Treating multiple-risk hypertensive populations..  12:121S-129S. 1999
  • Fenoldopam: A new parenteral antihypertensive: Consensus roundtable on the management of perioperative hypertension and hypertensive crises.  12:653-664. 1999
  • A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.  12:414-417. 1999
  • A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension..  12:414-417. 1999
  • Management of the hypertensive patient with coronary artery disease..  12:56S-62S. 1999
  • Management of the hypertensive patient with coronary artery disease.  12:56S-62S. 1999
  • Treating multiple-risk hypertensive populations.  12:121-129. 1999
  • Case study.  11. 1998
  • The evolving role of angiotensin-II receptor blockers in cardiovascular risk reduction. Case study..  11:192S-194S. 1998
  • Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension..  11:88S-94S. 1998
  • Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension.  11:31-40. 1998
  • Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension..  11:31-40. 1998
  • Mibefradil, a T-channel-selective calcium antagonist: Clinical trials in hypertension.  11:88S-94S. 1998
  • Vascular compliance and cardiovascular disease: A risk factor or a marker?.  10:1175-1189. 1997
  • Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.  10:735-742. 1997
  • Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension..  10:735-742. 1997
  • The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group..  10:705-713. 1997
  • ALLHAT and calcium channel blockers [3].  10:142-143. 1997
  • ALLHAT and calcium channel blockers. ALLHAT Research Group..  10:142-143. 1997
  • Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients.  10:68-76. 1997
  • Erratum: Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension (American Journal of Hypertension (July 1997) 10 (735-742)).  10:1081. 1997
  • The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study rationale, design, and methods.  10:705-713. 1997
  • Lack of independent relationships between left ventricular mass and cardiovascular reactivity to physical and psychological stress in the coronary artery risk development in young adults (CARDIA) study.  9:915-923. 1996
  • Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group..  9:342-360. 1996
  • Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT).  9:342-360. 1996
  • Pressor and bradykardie effects of centrally administered relaxin in conscious rats.  8:375-381. 1995
  • Effects of acute and chronic blockade of neutral endopeptidase with Sch 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats..  5:210-218. 1992
  • Effects of acute and chronic blockade of neutral endopeptidase with sch 34826 on nacl-sensitive hypertension in spontaneously hypertensive rats.  5:210-218. 1992
  • Ganglion atrial natriuretic peptide in nacl sensitive spontaneously hypertensive rats.  5:806-810. 1992
  • The calcium antagonists in the 1990s. An overview..  4:396S-405S. 1991
  • Altered stores of atrial natriuretic peptide in specific brain nuclei of NaCl-sensitive spontaneously hypertensive rats..  4:449-455. 1991
  • Altered stores of atrial natriuretic peptide in specific brain nuclei of nacl-sensitive spontaneously hypertensive rats.  4:449-455. 1991
  • Diagnosis of renovascular hypertension after renal transplantation.  4:724S-730S. 1991
  • Report of the working party group on determining the radionuclide of choice.  4:747S-748S. 1991
  • The calcium antagonists in the 1990s an overview.  4:396S-405S. 1991
  • Dietary Ca2+ prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanism..  3:179S-188S. 1990
  • Dietary ca2+prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanism.  3:179S-188S. 1990
  • Central mechanisms of hypertension..  2:477-485. 1989
  • Dietary NaCl loading enhances antihypertensive effect of guanabenz in spontaneously hypertensive rats..  2:435-439. 1989
  • Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension..  2:154-157. 1989
  • Central mechanisms of hypertension.  2:477-485. 1989
  • Dietary NaCl loading enhances antihypertensive effect of guanabenz in spontaneously hypertensive rats.  2:435-439. 1989
  • Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension.  2:154-157. 1989
  • International Standard Serial Number (issn)

  • 0895-7061
  • Electronic International Standard Serial Number (eissn)

  • 1941-7225